Aviram M, Bierman E L, Chait A
Department of Medicine, University of Washington, Seattle 98195.
J Biol Chem. 1988 Oct 25;263(30):15416-22.
Incubation of low density lipoprotein(s) (LDL) with either lipoprotein lipase or hepatic lipase led to modification of the core lipid composition of LDL. Both lipases modified LDL by substantially reducing core triglyceride content without producing marked differences in size, charge, or lipid peroxide content in comparison to native LDL. The triglyceride-depleted forms of LDL that result from treatment with these two enzymes were degraded at approximately twice the rate of native LDL by human monocyte-derived macrophages (HMDM). Lipase-modified LDL degradation was inhibited by chloroquine, suggesting lysosomal involvement in LDL cellular processing. The increased degradation by macrophages of the LDL modified by these lipases was accompanied by enhanced cholesterol esterification rates, as well as by an increase in cellular free and esterified cholesterol content. In a patient with hepatic triglyceride lipase deficiency, degradation of the triglyceride-rich LDL by HMDM was approximately half that of normal LDL. Following in vitro incubation of LDL from this patient with either lipoprotein or hepatic lipase, lipoprotein degradation increased to normal. Several lines of evidence indicate that LDL modified by both lipases were taken up by the LDL receptor and not by the scavenger receptor. 1) The degradation of lipase-modified LDL in nonphagocytic cells (human skin fibroblast and arterial smooth muscle cells) as well as in phagocytic cells (HMDM, J-774, HL-60, and U-937 cell lines) could be dissociated from that of acetylated LDL and was always higher than that of native LDL. A similar pattern was found for cellular cholesterol esterification and cholesterol mass. 2) LDL receptor-negative fibroblasts did not degrade lipase-modified LDL. 3) A monoclonal antibody to the LDL receptor inhibited macrophage degradation of the lipase-modified LDL. 4) Excess amounts of unlabeled LDL competed substantially with 125I-labeled lipase-modified LDL for degradation by both macrophages and fibroblasts. Thus, lipase-modified LDL can cause significant cholesterol accumulation in macrophages even though it is taken up by LDL and not by the scavenger receptor. This effect could possibly be related to the reduced triglyceride content in the core of LDL, which may alter presentation of the LDL receptor-binding domain of apolipoprotein B on the particle surface, thereby leading to increased recognition and cellular uptake via the LDL receptor pathway.
低密度脂蛋白(LDL)与脂蛋白脂肪酶或肝脂肪酶一起孵育会导致LDL核心脂质组成发生改变。两种脂肪酶都通过大幅降低核心甘油三酯含量来修饰LDL,与天然LDL相比,在大小、电荷或脂质过氧化物含量方面没有产生明显差异。用这两种酶处理后产生的甘油三酯耗尽型LDL,被人单核细胞衍生巨噬细胞(HMDM)降解的速度约为天然LDL的两倍。脂肪酶修饰的LDL降解受到氯喹的抑制,表明溶酶体参与了LDL的细胞处理过程。这些脂肪酶修饰的LDL被巨噬细胞降解增加的同时,胆固醇酯化率也增强,细胞游离胆固醇和酯化胆固醇含量也增加。在一名患有肝甘油三酯脂肪酶缺乏症的患者中,HMDM对富含甘油三酯的LDL的降解约为正常LDL的一半。将该患者的LDL与脂蛋白或肝脂肪酶进行体外孵育后,脂蛋白降解增加至正常水平。几条证据表明,两种脂肪酶修饰的LDL是通过LDL受体而非清道夫受体被摄取的。1)脂肪酶修饰的LDL在非吞噬细胞(人皮肤成纤维细胞和动脉平滑肌细胞)以及吞噬细胞(HMDM、J - 774、HL - 60和U - 937细胞系)中的降解与乙酰化LDL的降解可分离,且总是高于天然LDL的降解。细胞胆固醇酯化和胆固醇总量也发现了类似模式。2)LDL受体阴性的成纤维细胞不降解脂肪酶修饰的LDL。3)一种针对LDL受体的单克隆抗体抑制巨噬细胞对脂肪酶修饰的LDL的降解。4)过量的未标记LDL与125I标记的脂肪酶修饰的LDL在被巨噬细胞和成纤维细胞降解方面存在显著竞争。因此,脂肪酶修饰的LDL即使通过LDL受体而非清道夫受体被摄取,也能在巨噬细胞中导致显著的胆固醇积累。这种效应可能与LDL核心中甘油三酯含量降低有关,这可能会改变载脂蛋白B在颗粒表面的LDL受体结合域的呈现,从而导致通过LDL受体途径的识别增加和细胞摄取增加。